Ribociclib effective in HR+, HER2– breast cancer
Crossref DOI link: https://doi.org/10.1038/s41571-018-0059-2
Published Online: 2018-06-21
Published Print: 2018-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sidaway, Peter
Text and Data Mining valid from 2018-06-21
Article History
First Online: 21 June 2018